Some studies have demonstrated that the absence of hENT1 as assessed by immunohistochemistry in tumor tissue was associated with shortened survival in gemcitabine-treated patients with PDA and have proposed hENT1 expression as a prognostic biomarker for gemcitabine sensitivity (27). Here, SLC29A1 is linked to Patent ductus arteriosus.